Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Novel HoloMonitor method identifies tumor creating cancer cells
Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.
New CEO commentary: “The scientific role of commercialization”
On PHI’s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”, see CEO commentary The scientific role of commercialization, published February 18, 2018.
PHI and Germany’s federal institute for materials research pursue joint patent application
Phase Holographic Imaging (PHI) and Germany’s federal institute for materials research (BAM) has agreed to jointly enter the national phase of international patent application “Molecularly Imprinted Polymers” in Europe, USA, China and Japan. An international patent application is a preliminary review prior to national applications. Patents are only granted nationally.
PHI Launches Wound Healing Assay
HoloMonitor® Wound Healing Assay: The assay meets the unmet market demand of both quantifying cell movement automatically and in great detail. Wound healing assays are one of the most used laboratory methods to study cell movement. Conventional wound healing assays are either manual or just measure the collective movement of a cell population.
Option Exercised IV
Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.
Options Exercised III
Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company
Leading Australian Research Institute Purchases HoloMonitor
A first HoloMonitor was recently deployed at QIMR Berghofer Medical Research Institute in Brisbane Australia. With the purchase, the institute upgrades its quantitative time-lapse cytometry capacity to also include instrumentation for measuring the behavior of individual cells in a cell population, without requiring the cells to be labeled with toxic chemicals or through genetic manipulation.
Options Exercised II
Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.
Options Exercised I
Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.
Novel HoloMonitor based research to be presented at cancer research annual meeting
Using HoloMonitor® technology from PHI the scientists have been able to follow and measure important dynamics of cancer cells in ways not possible with conventional methods, which has led to the novel research results.